Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A retrospective cohort study with adequate sample size and long follow-up (median 63 months) reporting a clinically meaningful primary endpoint (delayed re-stoma-free survival), but lacks a comparator group and prospective design; results support the durability of sphincter-preserving surgery but require confirmation in prospective studies.
A retrospective single-center study using cross-validation in a small, heterogeneous cohort (152 patients, split by treatment) that reports surrogate endpoints (AUC) rather than clinical outcomes; radiomic findings did not improve on baseline models, limiting clinical utility.
Meta-analysis of public transcriptomic data identifying candidate biomarkers and immune signatures associated with neoadjuvant response in rectal cancer, but without clinical validation, prospective design, or outcome prediction model.
Retrospective single-centre cohort with modest follow-up (1.4 years median) and no randomization; observational associations with biomarkers and treatment types are hypothesis-generating rather than definitive.
A narrative framework review synthesizing evidence on technical difficulty, surgical quality assessment, and AI-enabled audit for minimally invasive D2 lymphadenectomy, proposing guidance for quality measurement and process review.
Single-center retrospective cohort identifying multiple independent risk factors for anastomotic leakage and demonstrating significant impact on 5-year survival and disease-free survival, but limited by retrospective design and modest sample size.
A single-center phase 2 trial with a meaningful primary endpoint (40% complete response) and acceptable safety, but limited by lack of control group, modest sample size, and single-center design requiring confirmation in larger studies.
Single-centre retrospective measurement study with no clinical outcome; demonstrates a technical phenomenon (tissue shrinkage) but lacks comparison to patient safety or oncological adequacy thresholds.